CD138+ plasma cell levels in the CSF of natalizumab-treated patients with MS are significantly lower compared with those of patients with other neurological diseases and untreated patients with MS but increase after discontinuation of natalizumab (19). Here, SDC1 is linked to myeloid sarcoma.